Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INTROPIN vs GUAIFENESIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dopamine is a direct agonist at dopamine (D1 and D2) and beta-1 adrenergic receptors, and at higher doses, alpha-1 adrenergic receptors. It also causes release of norepinephrine from sympathetic nerve terminals.
Guaifenesin is an expectorant that increases respiratory tract fluid secretion and reduces mucus viscosity, facilitating expectoration.
Hemodynamic support in cardiogenic shock,Hypotension not due to hypovolemia,Adjunct in cardiopulmonary resuscitation,Off-label: Bradycardia unresponsive to atropine
Relief of productive cough associated with respiratory tract infections and common cold,Off-label: use as a muscle relaxant (unproven)
2-20 mcg/kg/min continuous IV infusion, titrated to achieve desired hemodynamic response. Typical initial dose: 5 mcg/kg/min.
Oral: 200-400 mg every 4 hours as needed, not to exceed 2400 mg/day.
Approximately 2 minutes. Short half-life allows rapid titration by intravenous infusion; effects cease within 5-10 minutes of discontinuation.
Terminal elimination half-life: 3-5 hours; clinical context: requires dosing every 4-6 hours for sustained mucolytic effect
Metabolized in the liver, kidney, and plasma by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) to inactive metabolites.
Primarily hepatic via oxidation and demethylation; major metabolite is beta-(2-methoxyphenoxy)lactic acid. CYP450 enzymes not significantly involved.
Primarily renal: 80% as unchanged drug and 20% as inactive metabolites (normetanephrine, homovanillic acid). Biliary/fecal excretion is negligible (<2%).
Renal: ~95% (primarily as unchanged drug and glucuronide conjugate); biliary/fecal: minimal (<5%)
25%, primarily to albumin.
~50% (bound to albumin)
0.2 L/kg (0.16-0.24 L/kg). Small Vd indicates limited extravascular distribution; compatible with rapid onset and offset.
~1 L/kg; clinical meaning: extensive distribution into extravascular tissues, including respiratory secretions
Oral: less than 5% due to extensive first-pass metabolism (MAO and COMT). Intramuscular: variable but limited due to peripheral vasoconstriction; not recommended.
Oral: 80-85% (first-pass metabolism minimal)
No specific GFR-based dose adjustment required; monitor for renal perfusion adequacy and adjust based on clinical response.
No specific guidelines; use caution in severe impairment due to potential accumulation of metabolites.
No specific Child-Pugh-based adjustment; use with caution in severe hepatic impairment due to altered metabolism.
No adjustment required for mild to moderate impairment; insufficient data for severe impairment.
0.5-20 mcg/kg/min continuous IV infusion; typical initial dose 2-5 mcg/kg/min, titrated to effect.
Children 2-5 years: 50-100 mg every 4 hours, max 600 mg/day; 6-11 years: 100-200 mg every 4 hours, max 1200 mg/day; ≥12 years: same as adult.
Start at lower end of dosing range (2-5 mcg/kg/min) due to increased sensitivity and comorbid conditions; titrate cautiously.
No specific adjustment; use lowest effective dose due to increased sensitivity and risk of adverse effects.
None
None
Can cause ectopic heartbeats, tachycardia, angina, palpitations, vasoconstriction, and hypertension,May increase myocardial oxygen demand,Risk of tissue necrosis with extravasation,Use with caution in patients with occlusive vascular disease,Hypovolemia should be corrected before administration
Use with caution in patients with persistent or chronic cough (e.g., smoking, asthma, COPD); if cough persists >7 days or recurs, or with fever/rash/headache, discontinue and evaluate.
Pheochromocytoma,Uncorrected tachyarrhythmias,Hypersensitivity to sulfites (if formulation contains sulfites),Ventricular fibrillation
Hypersensitivity to guaifenesin or any component of the formulation.
No significant food interactions. However, patients on INTROPIN may have underlying conditions requiring dietary modifications (e.g., low sodium for hypertension). Avoid tyramine-rich foods if also taking MAOIs, though not a direct interaction with dopamine itself.
No significant food interactions. Alcohol may exacerbate CNS depressant effects.
Pregnancy Category C. In first trimester, animal studies show fetal abnormalities (e.g., skeletal and visceral malformations) at high doses. Second and third trimesters: risk of reduced uteroplacental blood flow and fetal hypoxia due to vasoconstriction; may induce preterm labor.
Insufficient human data; animal studies show no evidence of fetal harm. Generally considered low risk across all trimesters, though use in first trimester should be cautious due to lack of robust data.
Excreted in breast milk in low concentrations; M/P ratio unknown. Potential for cardiovascular effects in infant; weigh benefits against risks.
Excretion into breast milk is likely minimal; M/P ratio not established. AAP considers compatible with breastfeeding; avoid excessive doses.
No specific dose adjustment required; start at low doses and titrate to effect due to altered hemodynamics and increased plasma volume in pregnancy.
No dosage adjustment necessary. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) are not clinically significant for guaifenesin.
INTROPIN (dopamine) is a catecholamine with dose-dependent effects: low dose (1-5 mcg/kg/min) stimulates D1 receptors causing renal vasodilation; intermediate dose (5-10 mcg/kg/min) activates β1 receptors increasing cardiac contractility and heart rate; high dose (>10 mcg/kg/min) stimulates α1 receptors leading to vasoconstriction. Monitor for extravasation as it can cause tissue necrosis; treat with phentolamine infiltration. Taper infusion gradually to avoid hypotension. Contraindicated in pheochromocytoma and uncorrected tachyarrhythmias.
Guaifenesin is an expectorant that increases respiratory tract fluid to reduce mucus viscosity. Onset of action is about 30 minutes; duration is 4-6 hours. Maximum effect requires adequate hydration. Avoid in persistent cough due to smoking, asthma, or emphysema. Use caution in renal impairment (Cr Cl <30 m L/min). Not recommended for children under 6 years without medical advice.
This medication is given intravenously and requires continuous monitoring in a hospital setting.,Report any pain, burning, or swelling at the IV site immediately.,You may experience increased heart rate, chest pain, or shortness of breath; notify staff promptly.,Inform your healthcare provider if you have a history of irregular heartbeat, high blood pressure, or thyroid disease.,Do not stop or change the infusion rate; it is controlled by medical staff.
Drink plenty of water while taking this medication to help loosen mucus.,Do not take for more than 7 days unless directed by a doctor.,Stop use and consult a doctor if cough persists for more than 7 days, is accompanied by fever, rash, or persistent headache.,Avoid alcohol as it may increase dizziness or drowsiness.,Do not crush or chew extended-release tablets; swallow whole.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about INTROPIN vs GUAIFENESIN, answered by our medical review team.
INTROPIN is a Catecholamine Vasopressor that works by Dopamine is a direct agonist at dopamine (D1 and D2) and beta-1 adrenergic receptors, and at higher doses, alpha-1 adrenergic receptors. It also causes release of norepinephrine from sympathetic nerve terminals.. GUAIFENESIN is a Expectorant that works by Guaifenesin is an expectorant that increases respiratory tract fluid secretion and reduces mucus viscosity, facilitating expectoration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INTROPIN and GUAIFENESIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INTROPIN is: 2-20 mcg/kg/min continuous IV infusion, titrated to achieve desired hemodynamic response. Typical initial dose: 5 mcg/kg/min.. The standard adult dose of GUAIFENESIN is: Oral: 200-400 mg every 4 hours as needed, not to exceed 2400 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between INTROPIN and GUAIFENESIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. INTROPIN is classified as Category C. Pregnancy Category C. In first trimester, animal studies show fetal abnormalities (e.g., skeletal and visceral malformations) at high doses. Second and third trimesters: risk of re. GUAIFENESIN is classified as Category C. Insufficient human data; animal studies show no evidence of fetal harm. Generally considered low risk across all trimesters, though use in first trimester should be cautious due to. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.